Hamacher to present at Good Neighbor Pharmacy annual conference
WAUKESHA, Wis. — Hamacher Resource Group will present at Good Neighbor Pharmacy’s ThoughtSpot Conference to be held June 20 to 23 in Las Vegas, the company announced Thursday.
Tom Boyer, a national account manager and part of the owners group at HRG, will present the continuing education session “Front-End: Cause & Effect” on June 21. The session is worth 1.5 CE credits for registered pharmacists.
“Participating once again at this conference is a great way for us to share our insights and knowledge with pharmacists to help them improve profits,” Boyer stated. We know pharmacists have a lot on their plate, and we provide them with actionable tips that will help them better serve their customers and increase revenue.”
During the session Boyer will reveal 15 strategies pharmacies can employ to increase their front-end sales by dedicating efforts to everything from cross-merchandising and customer service to inventory condition and new item additions.
A regular speaker at pharmacy schools and other industry events, Boyer also works directly with community-based pharmacies to assess and offer recommendations for improvements on everything from building exteriors to products on the shelves.
Reports: Diplomat to hire more veterans following White House economic summit
NEW YORK — Diplomat Specialty Pharmacy is looking to hire more veterans following an economic summit at the White House attended by CEO Phil Hagerman, according to published reports.
According to local media in Michigan, Hagerman brought up the idea after the summit, saying the "plight of unemployed veterans" was one of the takeaways from the event.
Flint, Mich.-based Diplomat announced last month that Hagerman had received an invitation to the event, sponsored by the White House Business Council and Business Forward, which was designed to explore opportunities for collaboration between the private sector and government.
FDA approves GSK, XenoPort drug for shingles pain
NEW YORK — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.
The drug makers announced Thursday the approval of Horizant (gabapentin enacarbil) extended-release tablets for managing post-herpetic neuralgia. The drug already had FDA approval for treating restless legs syndrome. The approval entitles XenoPort to a $10 million milestone payment from GSK, according to a collaborative agreement between the two companies.
The recommended dosage of the drug for managing post-herpetic neuralgia is a morning dose of 600 mg for three days followed by 600 mg twice daily starting on day four.